NEW YORK, March 31, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (NASDAQ:LFMD), a leading provider of virtual primary care services, today announced the launch of Novo Nordisk's new Wegovy® (semaglutide) subscription program — the first and only GLP-1 subscription offering of its kind — now available through LifeMD. The program meaningfully expands patient access to branded GLP-1 therapy and supports treatment adherence with significant cost savings.

The subscription model marks a significant evolution in branded GLP-1 distribution. Eligible patients who enroll in the multi-month Wegovy® program through LifeMD now benefit from structured pricing: up to $1,200 in annual savings for injectable formulations and $600 for oral therapy.

"Our inclusion in the Wegovy® subscription program is a natural extension of our established relationship with Novo Nordisk," said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "This program deepens the value of our collaboration and adds meaningful financial savings for the patients we serve. By integrating subscription pricing with our comprehensive remote patient care model, we're delivering the future of obesity treatment — branded therapy that is more accessible, affordable, and clinically supported."

Since its launch in 2025, LifeMD's collaboration with Novo Nordisk has expanded from an initial NovoCare® Pharmacy integration into a multi-faceted commercial collaboration spanning injectable and oral Wegovy® and Ozempic®. LifeMD is recognized as a telehealth provider on both the NovoCare® and Wegovy® websites — a distinction that underscores the depth and durability of the relationship.

Patients accessing Wegovy through LifeMD benefit from a comprehensive, end-to-end care experience that includes: virtual visits with LifeMD's affiliated medical group across all 50 states; ongoing clinical oversight and care management; access to nationwide diagnostic testing; and simplified billing and payment.

The Wegovy® subscription program is now available to eligible patients through LifeMD at https://lifemd.com/weight-management/.

About LifeMD, Inc.

LifeMD^® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men's and women's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit LifeMD.com.

Cautionary Note Regarding Forward Looking Statements

This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: "believe," "expect," "anticipate," "project," "should," "plan," "will," "may," "intend," "estimate," "predict," "continue," and "potential," or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.

Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, "Risk Factors" identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.

Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.

Investor Contact

Atul Kavthekar, Chief Financial Officer

investors@lifemd.com

Media Contact

Jessica Friedeman, Chief Business Officer

press@lifemd.com

LifeMD Offers Novo Nordisk's Industry-First Wegovy® Telehealth Subscription Program